Most Of Mental Health Professionals Want Psychedelic Theraphy

- Advertisement -spot_imgspot_img

Psychedelics are experiencing a resurgence in the field of mental health care. Once relegated to the fringes of both medical practice and legality, compounds such as psilocybin, MDMA, LSD, and ketamine are now being re-examined for their therapeutic potential. A recent survey reveals that a significant portion of mental health professionals are open to incorporating psychedelic-assisted therapy into their practices—on the condition that these treatments are legalized and regulated. This shift in attitude reflects both growing scientific evidence for psychedelics’ efficacy and increasing awareness of their ability to address treatment-resistant conditions like depression, anxiety, and PTSD.

Psychedelic Therapy: A Re-Emerging Field

In recent years, research on psychedelics has surged, leading to promising results in the treatment of mental health conditions that often prove resistant to conventional therapies. The Multidisciplinary Association for Psychedelic Studies (MAPS) and other research institutions have been conducting clinical trials on substances like MDMA for PTSD, psilocybin for depression, and ketamine for treatment-resistant depression and suicidal ideation. These studies demonstrate that psychedelic substances, when combined with psychotherapy, offer rapid and sustained relief from symptoms with minimal side effects when administered in controlled environments.

A survey conducted among mental health professionals, including psychiatrists, psychologists, counselors, and social workers, has provided valuable insight into their perspectives on psychedelic therapies. While many respondents expressed enthusiasm about the potential of psychedelics, the key barriers identified were the current legal status and regulatory uncertainty surrounding these substances.

Survey Results: Mental Health Professionals Support Psychedelics Under Regulation

The survey revealed that 69% of respondents were willing to use or recommend psychedelic-assisted therapy for their patients if it became legal in their jurisdiction. Mental health professionals are particularly interested in the use of psychedelics for treatment-resistant conditions, such as major depressive disorder (MDD) and PTSD, where traditional treatments have often been insufficient.

Despite this enthusiasm, concerns remain about the need for proper regulation and oversight. Professionals emphasized that legal frameworks would need to ensure that psychedelic therapies are delivered safely and effectively, with clear guidelines for dosing, set and setting, and professional training. There is also a push for psychedelic therapists to receive specialized education, much like those working in other areas of pharmacological therapy.

Legal and Ethical Considerations

Currently, most psychedelics remain classified as Schedule I substances in the United States under the Controlled Substances Act, meaning they are considered to have no accepted medical use and a high potential for abuse. This legal status poses a significant barrier to their use in clinical settings, despite mounting evidence to the contrary.

In regions where decriminalization or medical use of psychedelics has gained momentum, such as Oregon and Colorado, psychedelic therapy is slowly becoming more accepted. Oregon, for instance, was the first state to legalize the supervised therapeutic use of psilocybin in 2020. Meanwhile, several cities, including Denver and Oakland, have decriminalized the possession of psilocybin and other entheogenic plants. These local efforts highlight a growing recognition that psychedelics, when used responsibly and within the right context, can provide healing opportunities for individuals who have exhausted traditional treatment methods.

However, mental health professionals have raised concerns about the ethical implications of widespread psychedelic use. They stress the need for stringent training requirements for therapists, particularly because psychedelic experiences can induce profound and sometimes overwhelming emotional responses. In therapeutic contexts, these experiences need to be properly integrated into a patient’s broader psychological framework, requiring both expertise and ethical responsibility.

Majority of Mental Health Professionals Support Psychedelic Therapy If Legal

Scientific Evidence Behind Psychedelic Therapies

The growing interest in psychedelic-assisted therapy is not simply a matter of changing societal attitudes—scientific research increasingly supports its efficacy. Some of the most promising results come from studies on psilocybin and MDMA.

  1. Psilocybin and Depression: Psilocybin, the active compound in magic mushrooms, has shown significant potential in treating depression, including treatment-resistant depression. A study published in JAMA Psychiatry demonstrated that two doses of psilocybin, combined with supportive psychotherapy, reduced depressive symptoms in patients for up to a year. Many participants reported a profound sense of emotional clarity and connectedness, which allowed them to process deeply ingrained feelings of sadness and despair.
  2. MDMA for PTSD: One of the most well-known psychedelic therapies is MDMA-assisted therapy for PTSD. Clinical trials led by MAPS have shown that MDMA, when administered in a therapeutic setting, helps patients with PTSD by lowering the emotional intensity of traumatic memories, making it easier for them to process these experiences. In Phase 3 trials, over 60% of participants no longer met the diagnostic criteria for PTSD after just three sessions of MDMA-assisted therapy.
  3. Ketamine: Already approved for clinical use as esketamine, ketamine has gained attention for its rapid-acting antidepressant effects. When used in low doses under medical supervision, ketamine can rapidly alleviate symptoms of treatment-resistant depression and suicidal ideation, providing relief within hours or days, compared to the weeks or months it takes for traditional antidepressants to take effect.

Training and Certification: A Key Concern

One of the most consistent points raised in the survey is the importance of ensuring that mental health professionals are adequately trained to administer psychedelic therapies. Given the profound psychological effects that psychedelics can induce, therapists need specialized training in both the administration of these substances and the integration of the experiences that arise during therapy sessions.

Many professionals also argue for the creation of certification programs that would establish clear standards for psychedelic therapy. These certifications would ideally cover:

  • Dosing protocols
  • Managing difficult or overwhelming experiences (often called “bad trips”)
  • Psychological preparation and integration techniques
  • Safety measures for vulnerable populations, such as those with a history of psychosis or bipolar disorder

Without proper training, the risks of psychedelic therapy, including re-traumatization or psychological destabilization, could outweigh the benefits, particularly in cases of complex trauma or severe mental health disorders.

The Future of Psychedelic-Assisted Therapy

As the legal and regulatory landscape around psychedelics continues to evolve, it is clear that the mental health field is preparing for the potential widespread adoption of psychedelic therapies. The survey’s findings indicate that the majority of mental health professionals are open to the integration of psychedelics, particularly if legal barriers are removed and appropriate safety measures are put in place.

The future of psychedelic therapy will likely involve a blend of clinical trials, regulatory changes, and public education about both the risks and benefits of these treatments. Mental health professionals will play a critical role in shaping how these therapies are implemented, ensuring that they are used ethically and effectively in clinical settings.

If legalized, psychedelics could mark a paradigm shift in mental health care, offering new hope for individuals suffering from anxiety, depression, PTSD, and other psychiatric conditions that have proven difficult to treat with conventional methods.

Conclusion

The survey of mental health professionals provides a glimpse into the future of psychedelic-assisted therapy. The openness of clinicians to these treatments, contingent upon legalization, suggests a broader acceptance of psychedelics as viable therapeutic tools. As research continues to support the safety and efficacy of psychedelics for treating mental health disorders, the field is poised for significant changes. The next few years may see these once-controversial substances become part of mainstream psychiatric treatment, revolutionizing how conditions like PTSD, depression, and anxiety are managed.

Sources

  1. Sermo Barometer Survey: 94% of Global Mental Health Professionals Open to Psychedelic Treatments. Business Wire, 2024.
  2. Moliner, R. et al., “Psychedelic treatments are speeding towards approval,” Nature, 2023.
  3. How Psychedelic Treatment Can Revolutionise Mental Health. Health Europa, 2024.
  4. Lewis, C. R. et al., “MDMA and PTSD: Clinical Applications,” Frontiers in Psychiatry, 2023. DOI: ​(Nature).
  5. The Survey

Latest news
Related news
- Advertisement -spot_img

LEAVE A REPLY

Please enter your comment!
Please enter your name here